T-1101 Receives TFDA Approval for Phase II Clinical Trial, Advancing Development Milestone
Taivex announced that its investigational drug T-1101 has received approval from Taiwan’s Food and Drug Administration (TFDA) to initiate Phase II clinical trials. The study will further evaluate the safety and efficacy of T-1101 in patients with neuroendocrine tumors (NET), supporting the path toward future regulatory filings. T-1101 is a first-in-class oral small-molecule inhibitor …